PARTNER 3 at 5 Years: Low-Risk Patients and TAVI… Quo Vadimus?
Five-year results from the PARTNER 3 trial, which evaluated the balloon-expandable SAPIEN 3® TAVI versus surgical aortic valve replacement (SAVR) in low-risk patients.
Five-year results from the PARTNER 3 trial, which evaluated the balloon-expandable SAPIEN 3® TAVI versus surgical aortic valve replacement (SAVR) in low-risk patients.
Dr. Encarnación Gutiérrez’s review discusses the current state of managing infections associated with cardiac stimulation devices (CSDs), addressing the increase in associated costs due to three primary factors.
A retrospective study conducted by Yale University over three decades scrutinizes the data from its Aortic Institute to assess the validity of surgical indications for rapid growth exceeding 3 mm/year.
A retrospective study conducted in the United States analyzed the incidence, outcomes, and costs associated with heparin-induced thrombocytopenia (HIT) in patients undergoing cardiac surgery.
This retrospective study evaluates the frequency and clinical impact of thromboembolic complications following aortic arch repair utilizing the Frozen Elephant Trunk (FET) with the Thoraflex® device (Terumo Aortic®).
This study, conducted at a tertiary pediatric cardiology center, evaluates the long-term use of ventricular assist devices (VADs).
This single-center retrospective study analyzes the clinical and safety outcomes of leadless pacemakers in patients requiring permanent pacing after cardiac surgery or transcatheter valve intervention.
Update on the status of mitral valve replacement in pediatric patients, by expert Dr. María Luz Polo.
Retrospective, single-center study on the initial 50 cases of aortic root enlargement using Yang’s technique.
A meta-analysis by a Japanese research group compares mid-term survival outcomes for patients with concomitant aortic stenosis and coronary artery disease who underwent either entirely surgical or percutaneous treatment options.